echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ​Tecoro TDM-105795 Initiates Phase Ib Human Clinical Trial of Androgenetic Alopecia

    ​Tecoro TDM-105795 Initiates Phase Ib Human Clinical Trial of Androgenetic Alopecia

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 28, 2022, Tecoro Bio announced that its topical TDM-105795 tincture for patients with androgenetic alopecia (AGA) completed the first clinical phase 1b (MAD) trial in the United States on February 23 last week.
    All patients in each dose group were enrolled and started to administer the drug to the patients
    .

    The Phase 1b clinical trial is a 28-day multiple dose escalation study, which is a "randomized, double-blind, vehicle-controlled, parallel group, multiple dose escalation study to evaluate the efficacy of TDM-105795 in patients with androgenic Safety, tolerability and pharmacokinetics in healthy male subjects with alopecia
    .
    " Two U.
    S.
    clinical centers are currently participating in the study
    .

    About TDM-105795

    About TDM-105795

    TDM-105795 is a small molecule drug candidate that is a topical drug that promotes hair growth
    .
    The preclinical evaluation of TDM-105795 showed that TDM-105795 is systemically malabsorbed after topical administration and has a short elimination half-life, which is ideal for avoiding unwanted systemic effects
    .
    In addition, in vivo efficacy studies in C3H mice showed that TDM-105795, when applied topically, was able to stimulate hair growth depending on the dose used
    .
    This may be because TDM-105795 can activate dormant hair follicle stem cells when it binds to hair follicle cell target receptor proteins, and promote the rapid entry of hair follicles in the telogen phase (resting phase) into the anagen phase (anagen phase)
    .

    About Androgenetic Alopecia (AGA)

    About Androgenetic Alopecia (AGA)

    Androgenetic alopecia (AGA), also known as male or female pattern baldness, is the most common type of hair loss affecting both men and women, with a higher incidence in men
    .
    More than half of adult men have AGA, and this rate can rise to more than 80% in men 50 and older
    .
    Male AGA is characterized by a receding hairline and baldness on the crown and front of the head
    .
    AGA in women usually presents with thinning of the hair on the crown of the head
    .
    The etiology of hair loss is still unclear.
    Hair loss is a degenerative disease.
    Genetic, psychological, spiritual, endocrine and metabolic factors may cause hair loss
    .
    The pathogenesis of AGA is related to the overactivation of androgen receptors in hair follicle cells, which prevents quiescent hair follicles from re-entering the anagen phase, leading to follicle atrophy
    .

    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.